Quote | Hillstream BioPharma Inc. (NASDAQ:HILS)
Last: | $0.2305 |
---|---|
Change Percent: | -0.31% |
Open: | $0.225 |
Close: | $0.2305 |
High: | $0.2448 |
Low: | $0.2201 |
Volume: | 312,845 |
Last Trade Date Time: | 09/22/2023 03:00:00 am |
News | Hillstream BioPharma Inc. (NASDAQ:HILS)
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeu...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Message Board Posts | Hillstream BioPharma Inc. (NASDAQ:HILS)
Subject | By | Source | When |
---|---|---|---|
$HILS .4702 Randy Milby - CEO & Chairman | BooDog | investorshub | 04/28/2023 2:01:37 PM |
lol, yup. it's a wierd relationship when you | BooDog | investorshub | 04/28/2023 12:52:35 PM |
Yuck | Awl416 | investorshub | 04/28/2023 12:09:56 PM |
... today announced the pricing of an underwritten | BooDog | investorshub | 04/28/2023 10:20:25 AM |
$HILS MomentumIts now last up | harry crumb | investorshub | 04/27/2023 10:10:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Hillstream BioPharma Inc. Company Name:
HILS Stock Symbol:
NASDAQ Market:
Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeu...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic prur...